

Donald W Light

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11960413/publications.pdf>

Version: 2024-02-01

69
papers

2,055
citations

279798

23
h-index

254184

43
g-index

76
all docs

76
docs citations

76
times ranked

1469
citing authors

#	ARTICLE	IF	CITATIONS
1	Pharmaceutical research and development: what do we get for all that money?. <i>BMJ, The</i> , 2012, 345, e4348-e4348.	6.0	168
2	Demythologizing the high costs of pharmaceutical research. <i>BioSocieties</i> , 2011, 6, 34-50.	1.3	155
3	Uncertainty and Professional Work: Perceptions of Physicians in Clinical Practice. <i>American Journal of Sociology</i> , 1992, 97, 1022-1051.	0.5	130
4	Institutional Corruption of Pharmaceuticals and the Myth of Safe and Effective Drugs. <i>Journal of Law, Medicine and Ethics</i> , 2013, 41, 590-600.	0.9	112
5	The Rhetorics and Realities of Community Health Care: The Limits of Countervailing Powers to Meet the Health Care Needs of the Twenty-First Century. <i>Journal of Health Politics, Policy and Law</i> , 1997, 22, 105-145.	1.9	84
6	The Practice and Ethics of Risk-Rated Health Insurance. <i>JAMA - Journal of the American Medical Association</i> , 1992, 267, 2503.	7.4	83
7	Life on the edge: immigrants confront the American health system. <i>Ethnic and Racial Studies</i> , 2012, 35, 3-22.	2.3	82
8	Corporate Medicine for Profit. <i>Scientific American</i> , 1986, 255, 38-45.	1.0	77
9	From Managed Competition to Managed Cooperation: Theory and Lessons from the British Experience. <i>Milbank Quarterly</i> , 1997, 75, 297-341.	4.4	77
10	Market spiral pricing of cancer drugs. <i>Cancer</i> , 2013, 119, 3900-3902.	4.1	77
11	Managed competition, governmentality and institutional response in the United Kingdom. <i>Social Science and Medicine</i> , 2001, 52, 1167-1181.	3.8	66
12	Foreign free riders and the high price of US medicines. <i>BMJ: British Medical Journal</i> , 2005, 331, 958-960.	2.3	59
13	Extraordinary claims require extraordinary evidence. <i>Journal of Health Economics</i> , 2005, 24, 1030-1033.	2.7	52
14	Toward a New Sociology of Medical Education. <i>Journal of Health and Social Behavior</i> , 1988, 29, 307.	4.8	50
15	Universal Health Care: Lessons From the British Experience. <i>American Journal of Public Health</i> , 2003, 93, 25-30.	2.7	50
16	Manufacturing costs of HPV vaccines for developing countries. <i>Vaccine</i> , 2016, 34, 5984-5989.	3.8	50
17	Comparative institutional response to economic policy managed competition and governmentality. <i>Social Science and Medicine</i> , 2001, 52, 1151-1166.	3.8	41
18	Introduction: A sociological perspective on rationing: power, rhetoric and situated practices. <i>Sociology of Health and Illness</i> , 2001, 23, 551-569.	2.1	40

#	ARTICLE	IF	CITATIONS
19	Homo Economicus: escaping the traps of managed competition. <i>European Journal of Public Health</i> , 1995, 5, 145-154.	0.3	39
20	Estimated research and development costs of rotavirus vaccines. <i>Vaccine</i> , 2009, 27, 6627-6633.	3.8	37
21	Why do cancer drugs get such an easy ride?. <i>BMJ, The</i> , 2015, 350, h2068-h2068.	6.0	36
22	The Sociological Character of Health-Care Markets. , 0, , 394-408.		33
23	The costs of coronavirus vaccines and their pricing. <i>Journal of the Royal Society of Medicine</i> , 2021, 114, 502-504.	2.0	31
24	Life, Death, and the Insurance Companies. <i>New England Journal of Medicine</i> , 1994, 330, 498-500.	27.0	29
25	A Conservative Case for Universal Access to Health Care. <i>Hastings Center Report</i> , 2006, 36, 36-45.	1.0	26
26	Professionalism as a Countervailing Power. <i>Journal of Health Politics, Policy and Law</i> , 1991, 16, 499.1-506.	1.9	23
27	Values and Structure in the German Health Care Systems. <i>The Milbank Memorial Fund Quarterly Health and Society</i> , 1985, 63, 615.	0.8	22
28	Policy Making on Data Exclusivity in the European Union: From Industrial Interests to Legal Realities. <i>Journal of Health Politics, Policy and Law</i> , 2009, 34, 979-1010.	1.9	21
29	Historical and comparative reflections on the U.S. national health insurance reforms. <i>Social Science and Medicine</i> , 2011, 72, 129-132.	3.8	21
30	Escaping the traps of postwar Western medicine. <i>European Journal of Public Health</i> , 1993, 3, 281-289.	0.3	19
31	Good Managed Care Needs Universal Health Insurance. <i>Annals of Internal Medicine</i> , 1999, 130, 686.	3.9	18
32	Equity and efficiency in health care. <i>Social Science and Medicine</i> , 1992, 35, 465-469.	3.8	17
33	Setting the record straight in the reply by DiMasi, Hansen and Grabowski. <i>Journal of Health Economics</i> , 2005, 24, 1045-1048.	2.7	17
34	Categorical inequality, institutional ambivalence, and permanently failing institutions: the case of immigrants and barriers to health care in America. <i>Ethnic and Racial Studies</i> , 2012, 35, 23-39.	2.3	16
35	Benchmarks of Fairness: A Moral Framework for Assessing Equity. <i>International Journal of Health Services</i> , 1999, 29, 853-869.	2.5	15
36	Managed Care in a New Key: Britain's Strategies for the 1990s. <i>International Journal of Health Services</i> , 1998, 28, 427-444.	2.5	14

#	ARTICLE	IF	CITATIONS
37	Making Practical Markets for Vaccines. PLoS Medicine, 2005, 2, e271.	8.4	14
38	GAVI's Advance Market Commitment. Lancet, The, 2010, 375, 638.	13.7	14
39	Cost Containment and the Backdraft of Competition Policies. International Journal of Health Services, 2001, 31, 681-708.	2.5	13
40	Is G8 putting profits before the world's poorest children?. Lancet, The, 2007, 370, 297-298.	13.7	13
41	No Exit and the Organization of Voice in Biotechnology and Pharmaceuticals. Journal of Health Politics, Policy and Law, 2003, 28, 473-508.	1.9	11
42	Misleading Congress about Drug Development. Journal of Health Politics, Policy and Law, 2007, 32, 895-913.	1.9	11
43	The FDA's new clothes. BMJ, The, 2015, 351, h4897.	6.0	11
44	Is Competition Bad?. New England Journal of Medicine, 1983, 309, 1315-1319.	27.0	10
45	Good Pharma. , 2015, , .		9
46	Globalizing Restricted and Segmented Markets: Challenges to Theory and Values in Economic Sociology. Annals of the American Academy of Political and Social Science, 2007, 610, 232-245.	1.6	8
47	Saving the pneumococcal AMC and GAVI. Hum Vaccin, 2011, 7, 138-141.	2.4	8
48	Pharmaceuticals as a market for "elemons". Theory and practice. Social Science and Medicine, 2021, 268, 113368.	3.8	8
49	Be Clear About Managed Care to Get Clear About Doctor-Patient Relations. American Journal of Bioethics, 2006, 6, 35-36.	0.9	5
50	Pharmaceutical Research and Development: What Do We Get for All that Money?. SSRN Electronic Journal, 0, , .	0.4	5
51	Reflections on commissioning and the English coalition government NHS reforms. Social Science and Medicine, 2011, 72, 821-822.	3.8	4
52	Ironies of success: a new history of the American health care "system". Journal of Health and Social Behavior, 2004, 45 Suppl, 1-24.	4.8	4
53	The "American (cancer) patients first" plan to reduce drug prices" A critical assessment. American Journal of Hematology, 2018, 93, 1444-1450.	4.1	3
54	Addressing Health Care Disparities: A Radical Perspective and Proposal. Frontiers in Sociology, 2020, 5, 29.	2.0	3

#	ARTICLE	IF	CITATIONS
55	Pricing pharmaceutical drugs in the USA. , 2018, , 63-79.		3
56	Whatâ€™s So Great About Newness?. Health Affairs, 2007, 26, 1793-1793.	5.2	2
57	Commentary: The New Paternalism. Medical Care Research and Review, 1999, 56, 141-144.	2.1	1
58	Measuring Fairness: An Opportunity for Empirical Ethics. American Journal of Bioethics, 2004, 4, 105-106.	0.9	1
59	Exaggerating The Benefits Of The â€˜Decade Of Vaccinesâ€™. Health Affairs, 2011, 30, 2026-2026.	5.2	1
60	Pharmaceutical Sales Representatives and Patient Safety. Journal of General Internal Medicine, 2013, 28, 1394-1394.	2.6	1
61	Other Side Of British Health Reform. Health Affairs, 1992, 11, 280-281.	5.2	0
62	Longer Exclusivity Does Not Guarantee Better Drugs. Health Affairs, 2011, 30, 798-798.	5.2	0
63	Pioneering Ethical Trials for Integrated Research. , 2015, , 133-157.		0
64	International Campaigns against Harmful Regulations and Practices. , 2015, , 179-196.		0
65	Science-Based Initiatives against Dangerous or Useless Drugs. , 2015, , 161-178.		0
66	Good Science for Good Pharmaâ€™A Public-Health Model. , 2015, , 197-217.		0
67	A conservative case for universal health insurance. New Jersey Medicine: the Journal of the Medical Society of New Jersey, 2005, 102, 35-7.	0.0	0
68	Improving medical practice and the economy through universal health insurance. New Jersey Medicine: the Journal of the Medical Society of New Jersey, 2005, 102, 39-44.	0.0	0
69	Analysis from the grassroots: how does pollution exposure vary by race and income?. Journal of Health Politics, Policy and Law, 2006, 31, 1151-63.	1.9	0